Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck Vaccines Unit To Be Headed By U.S. Human Health President McGlynn

This article was originally published in The Pink Sheet Daily

Executive Summary

Margaret McGlynn will succeed Adel Mahmoud in overseeing four launches planned for 2005-2006, including HPV vaccine Gardasil.

You may also be interested in...

ProQuad Vaccine BLA Review Extended To September

FDA has extended its review of Merck's measles, mumps, rubella and varicella vaccine ProQuad by three months until Sept. 30

Merck CEO Clark Brings Managed Care Expertise To Post; Gilmartin Retires

Richard Clark's appointment signals the importance Merck is placing on managed care ahead of the January 2006 start of the Medicare drug benefit. Merck also is highlighting Clark's manufacturing expertise, but acknowledges he will rely on Merck Research Labs President Peter Kim for advice on R&D strategy.

Merck Plans Pharmaceutical-Style Launch For HPV Vaccine Gardasil

Gardasil's marketing model will be closer to a blockbuster pharmaceutical than to a traditional vaccine, CEO Gilmartin says. The company sees a parallel to the roll-out of Fosamax for osteoporosis.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts